LECT2 Polyclonal Antibody (ABP59109): Targeted Detection for the Hepatokine at the Immunity-Metabolism Interface
LECT2: The Hepatokine You're Probably Under-Measuring LECT2 (Leukocyte cell-derived chemotaxin-2) is a secreted 16-kDa protein that functions as a chemotactic factor for neutrophils and stimulates the growth of chondrocytes and osteoblasts[reference:12]. Originally identified as a neutrophil chemoattractant, LECT2 has since emerged as a hepatokine linking hepatic lipid metabolism to systemic insulin resistance, obesity-associated inflammation, and rheumatoid arthritis susceptibility[reference:13]. The detection challenge for LECT2 is practical: as a small secreted protein, it circulates at low concentrations and is often measured in serum, plasma, or conditioned media—matrices where nonspecific binding and low signal-to-noise ratios can undermine conventional antibody performance. Defined Epitope Targeting: Partial LECT2 Protein Region Abbkine's LECT2 Polyclonal Antibody (ABP59109) is raised against a synthesized peptide derived from part region of human…
TGFβ1 Polyclonal Antibody (ABP52598): C-Terminal Epitope Targeting for the Master Fibrotic Cytokine
TGFβ1 Detection: Distinguishing the Latent Complex from the Active Dimer TGFβ1 is the prototypical member of the TGF-beta superfamily—a secreted ligand that binds TGF-beta receptors, recruits SMAD transcription factors, and regulates proliferation, differentiation, and extracellular matrix production[reference:8]. Its dysregulation drives fibrosis, tumor progression, and Camurati-Engelmann disease[reference:9]. The detection challenge is biosynthetic: TGFβ1 is synthesized as a preproprotein that is proteolytically processed into a latency-associated peptide (LAP) and a mature peptide[reference:10]. The mature peptide exists in two states—a latent complex (mature dimer + LAP + latent TGF-beta binding protein) and an active form consisting solely of the mature peptide homodimer. Antibodies targeting the LAP region detect latent TGFβ1 but miss the active pool; antibodies targeting the mature region can detect both, but require careful…
NOS2 Polyclonal Antibody (ABP51974): Non-Phospho-Site Epitope Targeting for iNOS Research
The iNOS Detection Dilemma: Inducible Expression and Phospho-Interference NOS2 (inducible nitric oxide synthase, iNOS) is the cytokine-inducible isoform of nitric oxide synthase—expressed in liver, macrophages, and other tissues upon stimulation with lipopolysaccharide and pro-inflammatory cytokines[reference:5]. It produces nitric oxide as a biologic mediator in neurotransmission, antimicrobial defense, and antitumor activity[reference:6]. Unlike the constitutively expressed neuronal (nNOS/NOS1) and endothelial (eNOS/NOS3) isoforms, iNOS is transcriptionally silent in resting cells and requires de novo synthesis for activity. This inducible expression pattern makes accurate iNOS detection both critical (as a marker of inflammatory activation) and challenging (because baseline expression is near-zero, demanding high signal-to-noise performance). Non-Phosphorylation Site Immunogen: Y151 Context Abbkine's NOS2 Polyclonal Antibody (ABP51974) is raised against a synthesized peptide derived from human NOS2…
ADAR2 Polyclonal Antibody (ABP50601): Internal-Region Epitope Targeting for RNA Editing Research
The ADAR Family Specificity Challenge ADAR2 (Adenosine Deaminase RNA Specific B1, encoded by ADARB1) catalyzes the site-specific deamination of adenosine to inosine in double-stranded RNA—an editing event essential for recoding glutamate receptor subunits and diversifying the neuronal transcriptome[reference:3]. Its dysregulation has been linked to seizure susceptibility, ALS, and altered calcium permeability in neuronal AMPA receptors. The detection problem is familial: ADAR2 shares substantial structural homology with ADAR1 (ADAR) and ADAR3 (ADARB2), the two other members of the ADAR family. Antibodies raised against conserved deaminase domains or N-terminal regions can cross-react with ADAR1, generating false-positive signal in tissues where both editing enzymes are co-expressed. Strategic Epitope Selection: Internal Region (aa 450–530) Abbkine's ADAR2 Polyclonal Antibody (ABP50601) sidesteps this trap through internal-region immunogen…
ERK1/2 (phospho Thr202/Y204) Polyclonal Antibody (ABP50531): Dual-Phospho-Site Precision for MAPK Pathway Research
The ERK Activation Problem: One Antibody, Two Phospho-Sites ERK1/2 sits at the terminal node of the RAS-RAF-MEK-ERK cascade—the signaling axis that drives proliferation, differentiation, and cell cycle progression in response to extracellular cues[reference:0]. Its activation requires dual phosphorylation at Thr202 and Tyr204 within the activation loop, a molecular switch that converts ERK from a dormant kinase into a nuclear-translocating transcriptional regulator. The detection challenge is structural: antibodies raised against a single phospho-site (T202 or Y204 alone) can capture partially phosphorylated ERK species that lack full catalytic activity, generating a signal that overestimates pathway activation. Conversely, pan-ERK antibodies detect total ERK regardless of phosphorylation status, providing no information about the activation state. Dual-Phospho-Site Immunogen Design Abbkine's ERK1/2 (phospho Thr202/Y204) Polyclonal Antibody (ABP50531) is…
Cleaved-Caspase-9 p35 (D315) Polyclonal Antibody (ABP50010): Neo-Epitope Specificity for Apoptosis Initiation Research
The Caspase-9 Activation Problem: Total vs. Cleaved Caspase-9 is the initiator caspase of the intrinsic apoptosis pathway. It exists as an inactive proenzyme (46 kDa) that, upon apoptosome assembly, undergoes autoproteolytic processing at D315 to generate the active p35 large subunit (35 kDa)[reference:21]. This cleavage is the molecular commitment point for mitochondrial apoptosis—the event that distinguishes a cell that will die from one that has merely received a death stimulus. Yet antibodies raised against full-length caspase-9 or internal regions that are retained in the pro-form cannot distinguish the uncleaved zymogen from the active p35 fragment. A Western blot showing a 46-kDa band tells you caspase-9 is present; only a 35-kDa band tells you it has been activated. Neo-Epitope Strategy: Cleavage-Site-Specific Recognition Abbkine's Cleaved-Caspase-9…
FOXP3 Polyclonal Antibody (ABP0141): C-Terminal Epitope Targeting for Regulatory T-Cell Research
FOXP3: The Master Regulator with a Detection Problem FOXP3 (Forkhead box protein P3) is the master transcriptional regulator of regulatory T cells (Tregs)—the subset that enforces immune tolerance and restrains autoimmunity. Defects in FOXP3 cause IPEX syndrome (immunodeficiency polyendocrinopathy, enteropathy, X-linked), a devastating autoimmune disorder[reference:16]. In cancer, Treg infiltration suppresses anti-tumor immunity, making FOXP3 a critical biomarker for immunotherapy response. Yet FOXP3 detection in tissue sections faces a specificity challenge: FOXP3 belongs to the forkhead/winged-helix family of transcriptional regulators, and antibodies raised against conserved forkhead domains can cross-react with related family members, generating false-positive nuclear signal in non-Treg cells. Strategic Epitope Selection: C-Terminal Region Abbkine's FOXP3 Polyclonal Antibody (ABP0141) addresses this through strategic immunogen design: the antibody is raised against a synthesized peptide derived…
CD4 Monoclonal Antibody (ABM40070): Monoclonal Consistency for T-Cell and Immune Microenvironment Studies
The CD4 Antibody Variability Problem CD4 is the canonical marker of helper T cells—a membrane glycoprotein that interacts with MHC class II antigens, serves as the receptor for HIV, and functions to initiate or augment early T-cell activation[reference:9]. CD4 is also expressed beyond T lymphocytes, in B cells, macrophages, granulocytes, and specific brain regions, making it a versatile but demanding immunohistochemical target[reference:10]. The challenge for CD4 immunohistochemistry is reproducibility. Polyclonal anti-CD4 antibodies, by nature, comprise a heterogeneous pool of immunoglobulins with varying affinities for different epitopes, leading to lot-to-lot variability in staining intensity and cellular specificity. For longitudinal studies or multi-center collaborations, this variability is a silent source of irreproducible data. Monoclonal Advantage: Single-Epitope Consistency Abbkine's CD4 Monoclonal Antibody (ABM40070) is…
MYPT1 (phospho Thr853) Polyclonal Antibody (ABP55324): Site-Specific Precision for RhoA/ROCK Signaling Research
The MYPT1 Phosphorylation Puzzle MYPT1 (Myosin phosphatase target subunit 1), encoded by PPP1R12A, is the regulatory subunit of myosin phosphatase—the enzyme that dephosphorylates myosin light chain (MLC) and drives smooth muscle relaxation and non-muscle cell relaxation[reference:5]. The RhoA/ROCK pathway phosphorylates MYPT1 at Thr853, inactivating the phosphatase and tilting the balance toward contraction[reference:6]. This Thr853 phosphorylation event is the molecular readout of RhoA/ROCK activity—a pathway implicated in hypertension, cancer cell invasion, and fibrosis. Yet site-specific antibodies for Thr853 face a fundamental challenge: cross-reactivity with total MYPT1 or other phospho-sites (Thr696, Ser852) that can distort the apparent activation state of the pathway. Site-Specific Immunogen Design Abbkine's MYPT1 (phospho Thr853) Polyclonal Antibody (ABP55324) is raised against a synthesized peptide derived from human MYPT1 around the phosphorylation site…
DRP1 Polyclonal Antibody (ABP51203): Precision Epitope Targeting for Mitochondrial Fission Research
The DRP1 Phospho-Site Cross-Reactivity Trap DRP1 (Dynamin-related protein 1), encoded by DNM1L, is the master GTPase governing mitochondrial and peroxisomal fission—a process intimately linked to apoptosis, programmed necrosis, and the pathogenesis of neurological disorders including Alzheimer's disease and lethal encephalopathy due to defective mitochondrial fission[reference:0]. Quantifying DRP1 accurately is therefore foundational to mitochondrial dynamics research. Yet a persistent problem plagues conventional DRP1 antibodies: cross-reactivity with the phosphorylated form of DRP1. The S637 phosphorylation site on DRP1 is a critical regulatory switch—phosphorylation at S637 inhibits fission, while dephosphorylation activates it. Antibodies raised against full-length DRP1 or phospho-peptides often fail to distinguish total DRP1 from its inactive, S637-phosphorylated pool, generating signal that conflates two functionally opposing states. Epitope-Exclusive Design: Non-Phosphorylation Site of S637…
